Regenovo

Regenovo Biotechnology Co., Ltd. (Regenovo), is a leading international provider of comprehensive 3D printing technology solutions in the biomedical field. As a national high-tech enterprise, Regenovo is committed to the research and development of professional bioprinting technologies and equipment for the biomedical sector. It constructs a digital medical chain from medical information to customized 3D printed medical products, and owns a dual-core industrial consortium of "bioprinting + biomaterials." The company provides products and services to scientific fields such as scientific research, regenerative medicine, tissue engineering, drug development, and personalized medicine, as well as clinical applications. Its main business includes: providing new research tools for researchers in fields like life sciences and materials science: through 3D printing technology, biomaterials can be printed into novel structures or cells into tissue models, applicable to research in regenerative medicine, tissue engineering, cancer, stem cells, and medical polymer materials; offering new treatment methods for patients with tissue and organ defects: mimicking the anatomical structure of tissues and organs, printing functional tissues or organs using cells or printing tissue repair scaffolds using biomaterials to replace or repair damaged tissues and organs; providing pharmaceutical companies with new drug development and formulation technologies: printing functional human tissue models for drug screening and toxicity testing in vitro, bridging the gap between preclinical trials and clinical trials; printing drug-controlled release scaffolds with freely designed structures; and providing doctors with personalized custom medical aids: designing and printing personalized surgical simulations, surgical positioning, plastic surgery assistance, and rehabilitation aids.